StockData
Lakewood-Amedex Biotherapeutics Inc. logo

Lakewood-Amedex Biotherapeutics Inc. (LABT) stock

LABTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$0.21−0.00 (-2.23%)

Close on Nov 17, 2026Market cap $508.30KP/E –Yield –

Earnings

Lakewood-Amedex Biotherapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Lakewood-Amedex Biotherapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Lakewood-Amedex Biotherapeutics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Lakewood-Amedex Biotherapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Lakewood-Amedex Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K

See a number that looks wrong?